Skip to main content
Top
Published in:

01-11-2024 | Neutropenia | Research

Enhancing patient-centered care: a randomized study on G-CSF administration preferences in chemotherapy-induced neutropenia

Authors: Nathaniel Scher, Hanène Boudabous, Judith Partouche, Saeedeh Rezaee-Vessal, Paul Ihout, Claudia Rizzo, Hanah Lamallem, Olivier Bauduceau, Ilan Darmon, Marc Bollet, Clément Draghi, Alain Toledano

Published in: Supportive Care in Cancer | Issue 11/2024

Login to get access

Abstract

Purpose

Chemotherapy-induced neutropenia poses a significant risk to cancer patients, with pegfilgrastim being commonly used for its prevention. While pegfilgrastim can be administered via prefilled syringe or pen device, patient preferences and experiences with these delivery methods remain unclear.

Methods

We conducted a prospective, open-label, randomized, observational trial (NCT05910164) at the Rafael Institute, France, comparing patient preferences for pegfilgrastim administration using a prefilled syringe versus a prefilled pen device. Patients undergoing chemotherapy and requiring pegfilgrastim were enrolled and randomized 1:1 to receive either syringe or pen first, with crossover administration. Questionnaires assessed patient preferences, learning experiences, autonomy, pain levels, emotional responses, satisfaction with nursing care, and empowerment.

Results

Among 150 randomized patients (mean age 58 years; 69% female), both groups showed a preference for the pen device, with significantly higher mean scores favoring pen administration (4.94 ± 1.70 vs. 4.27 ± 1.84; p = 0.00106). Patients reported significantly lower perceived pain with pen administration and stronger positive emotions compared to syringe use. Satisfaction with nursing care was higher with syringe use. Empowerment levels were similar across groups but significantly stronger when using the pen in complete autonomy.

Conclusion

A preference for pegfilgrastim administration via the pen device was observed, though this may have been influenced by the administration sequence and the absence of syringe self-administration. The insights gained can help inform clinical decision-making and improve patient-centered care in managing chemotherapy-induced neutropenia.

Trial registration

NCT05910164 on June 15, 2023.
Appendix
Available only for authorised users
Literature
6.
go back to reference Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, Dinner S, Geyer M, Glaspy J, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Mahajan A, Miller R, Nachar V, Patel S, Patel S, Perez LE, Poust A, Riaz F, Rosovsky R, Rugo HS, Simon S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Berardi RA, Pluchino L (2022) NCCN Guidelines® insights: hematopoietic growth factors, version 1.2022. J Natl Compr Canc Netw. 20(5):436–442. https://doi.org/10.6004/jnccn.2022.0026CrossRefPubMed Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, Dinner S, Geyer M, Glaspy J, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Mahajan A, Miller R, Nachar V, Patel S, Patel S, Perez LE, Poust A, Riaz F, Rosovsky R, Rugo HS, Simon S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Berardi RA, Pluchino L (2022) NCCN Guidelines® insights: hematopoietic growth factors, version 1.2022. J Natl Compr Canc Netw. 20(5):436–442. https://​doi.​org/​10.​6004/​jnccn.​2022.​0026CrossRefPubMed
8.
go back to reference Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for Research and Treatment of Cancer (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer (Oxford, England : 1990) 47(1):8–32. https://doi.org/10.1016/j.ejca.2010.10.013CrossRef Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for Research and Treatment of Cancer (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer (Oxford, England : 1990) 47(1):8–32. https://​doi.​org/​10.​1016/​j.​ejca.​2010.​10.​013CrossRef
9.
go back to reference Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 24(19):3187–205. https://doi.org/10.1200/JCO.2006.06.4451CrossRefPubMed Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 24(19):3187–205. https://​doi.​org/​10.​1200/​JCO.​2006.​06.​4451CrossRefPubMed
12.
go back to reference Metz M, Semsek D, Rogmans G, Hutzschenreuter U, Fietz T, Harde J, Zacharias S, Hielscher C, Lorenz A, Zahn MO, Guth D, Liebers S, Berghorn M, Grebhardt S, Matillon CD, Egerer G, Potthoff K (2021) Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients. Support Care Cancer. 29(11):6633–6643. https://doi.org/10.1007/s00520-021-06230-9CrossRefPubMedPubMedCentral Metz M, Semsek D, Rogmans G, Hutzschenreuter U, Fietz T, Harde J, Zacharias S, Hielscher C, Lorenz A, Zahn MO, Guth D, Liebers S, Berghorn M, Grebhardt S, Matillon CD, Egerer G, Potthoff K (2021) Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients. Support Care Cancer. 29(11):6633–6643. https://​doi.​org/​10.​1007/​s00520-021-06230-9CrossRefPubMedPubMedCentral
Metadata
Title
Enhancing patient-centered care: a randomized study on G-CSF administration preferences in chemotherapy-induced neutropenia
Authors
Nathaniel Scher
Hanène Boudabous
Judith Partouche
Saeedeh Rezaee-Vessal
Paul Ihout
Claudia Rizzo
Hanah Lamallem
Olivier Bauduceau
Ilan Darmon
Marc Bollet
Clément Draghi
Alain Toledano
Publication date
01-11-2024
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 11/2024
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-024-08929-x

Other articles of this Issue 11/2024

Supportive Care in Cancer 11/2024 Go to the issue
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

  • Webinar | 01-10-2024 | 12:30 (CEST)

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Get a reminder for the on-demand version